Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.0 - 0.0
Trade Value (12mth)
N/A
1 week
0%
1 month
-11.9%
YTD
-38.33%
1 year
-31.48%
All time high
N/A
EPS 3 yr Growth
N/A
EBITDA Margin
N/A
Operating Cashflow
N/A
Free Cash Flow Return
N/A
ROIC
N/A
Interest Coverage
N/A
Quick Ratio
N/A
Shares on Issue (Fully Dilluted)
N/A
HALO Sector
Healthcare
Next Company Report Date
N/A
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
N/A
Short Sell (% of issue)
N/A
Date | Announcements |
---|---|
31 October 23 |
Sep23 Quarterly Activities Report
×
Sep23 Quarterly Activities Report |
31 October 23 |
Sep23 Appendix 4C
×
Sep23 Appendix 4C |
31 October 22 |
Quarterly Appendix 4C Cash Flow Report
×
Quarterly Appendix 4C Cash Flow Report |
31 October 22 |
Quarterly Activities Report
×
Quarterly Activities Report |
31 May 22 |
Chairman's address
×
Chairman's address |
31 May 22 |
AGM Presentation
×
AGM Presentation |
31 May 22 |
Results of Meeting
×
Results of Meeting |
31 March 22 |
Annual Report to shareholders
×
Annual Report to shareholders |
31 March 22 |
Appendix 4G & Corporate Governance Statement
×
Appendix 4G & Corporate Governance Statement |
31 July 23 |
Quarterly Appendix 4C Cash Flow Report
×
Quarterly Appendix 4C Cash Flow Report |
31 July 23 |
Quarterly Activities Report
×
Quarterly Activities Report |
31 January 23 |
Quarterly Appendix 4C Cash Flow Report
×
Quarterly Appendix 4C Cash Flow Report |
31 January 23 |
Quarterly Activities Report
×
Quarterly Activities Report |
31 January 22 |
Quarterly Appendix 4C Cash Flow Report
×
Quarterly Appendix 4C Cash Flow Report |
31 January 22 |
Quarterly Activities Report
×
Quarterly Activities Report |
31 August 22 |
Half Yearly Report and Accounts
×
Half Yearly Report and Accounts |
30 October 23 |
IRX presents at AusBioInvest 2023
×
IRX presents at AusBioInvest 2023 |
30 March 23 |
Appendix 4G & Corporate Governance Statement
×
Appendix 4G & Corporate Governance Statement |
30 March 23 |
Annual Report to shareholders
×
Annual Report to shareholders |
30 March 22 |
IRX granted wholesale licenses for scheduled substances
×
IRX granted wholesale licenses for scheduled substances |
29 December 21 |
InhaleRx Ltd appoints Executive Director
×
InhaleRx Ltd appoints Executive Director |
29 April 22 |
Quarterly Appendix 4C Cash Flow Report
×
Quarterly Appendix 4C Cash Flow Report |
29 April 22 |
Quarterly Activities Report
×
Quarterly Activities Report |
28 July 22 |
Quarterly Appendix 4C Cash Flow Report
×
Quarterly Appendix 4C Cash Flow Report |
28 July 22 |
Quarterly Activities Report
×
Quarterly Activities Report |
28 February 22 |
Preliminary Final Report
×
Preliminary Final Report |
28 April 23 |
Quarterly Appendix 4C Cash Flow Report
×
Quarterly Appendix 4C Cash Flow Report |
28 April 23 |
Quarterly Activities Report
×
Quarterly Activities Report |
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.